Sagimet Biosciences (SGMT) Stock Forecast, Price Target & Predictions

SGMT Stock Forecast

Sagimet Biosciences stock forecast is as follows: an average price target of $6.00 (represents a 36.05% upside from SGMT’s last price of $4.41) and a rating consensus of 'Buy', based on 6 wall street analysts offering a 1-year stock forecast.

SGMT Price Target

The average price target for Sagimet Biosciences (SGMT) is $6.00 based on 1-year price targets from 6 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 36.05% upside from SGMT's last price of $4.41.

SGMT Analyst Ratings

Buy

According to 6 Wall Street analysts, Sagimet Biosciences's rating consensus is 'Buy'. The analyst rating breakdown for SGMT stock is 0 'Strong Buy' (0.00%), 5 'Buy' (83.33%), 1 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Sagimet Biosciences Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Jun 28, 2024	Andrea Tan	Goldman Sachs	$6.00	$4.11	45.99%	36.05%

Row per page

Go to

The latest Sagimet Biosciences stock forecast, released on Jun 28, 2024 by Andrea Tan from Goldman Sachs, set a price target of $6.00, which represents a 45.99% increase from the stock price at the time of the forecast ($4.11), and a 36.05% increase from SGMT last price ($4.41).

Sagimet Biosciences Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$6.00
Last Closing Price	$4.41	$4.41	$4.41
Upside/Downside	-100.00%	-100.00%	36.05%

In the current month, the average price target of Sagimet Biosciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Sagimet Biosciences's last price of $4.41. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 18, 2024	H.C. Wainwright	Buy	Buy	Hold
Oct 01, 2024	Leerink Partners	Outperform	Outperform	Hold
Aug 15, 2024	JMP Securities	Outperform	Outperform	Hold
Jun 28, 2024	Goldman Sachs	Buy	Neutral	Downgrade
May 24, 2024	Cowen & Co.	Buy	Buy	Hold
May 02, 2024	H.C. Wainwright	-	Buy	Initialise
Aug 08, 2023	Piper Sandler	-	Overweight	Initialise
Aug 08, 2023	Goldman Sachs	-	Buy	Initialise
Aug 08, 2023	JMP Securities	-	Market Outperform	Initialise

Row per page

Go to

Sagimet Biosciences's last stock rating was published by H.C. Wainwright on Nov 18, 2024. The company gave SGMT a "Buy" rating, the same as its previous rate.

Sagimet Biosciences Financial Forecast

Sagimet Biosciences Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
Revenue	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	$3.33M	-	-	-	-	-	-
High Forecast	-	-	-	-	$3.33M	-	-	-	-	-	-
Low Forecast	-	-	-	-	$3.33M	-	-	-	-	-	-
# Analysts	-	-	-	-	1	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Sagimet Biosciences's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. SGMT's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Sagimet Biosciences EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	1	-	-	-	-	-	-
EBITDA	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	$2.00M	-	-	-	-	-	-
High Forecast	-	-	-	-	$2.00M	-	-	-	-	-	-
Low Forecast	-	-	-	-	$2.00M	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

undefined analysts predict SGMT's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Sagimet Biosciences's previous annual EBITDA (undefined) of $NaN.

Sagimet Biosciences Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	1	-	-	-	-	-	-
Net Income	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-33.75M	$-32.46M	$-31.50M	$-31.82M	$-28.63M	$-28.20M	$-26.88M	$-21.82M	$-18.01M	$-12.48M	$-10.58M
High Forecast	$-33.75M	$-32.46M	$-31.50M	$-31.82M	$-28.63M	$-28.20M	$-26.88M	$-18.02M	$-15.44M	$-12.48M	$-10.58M
Low Forecast	$-33.75M	$-32.46M	$-31.50M	$-31.82M	$-28.63M	$-28.20M	$-26.88M	$-25.61M	$-21.35M	$-12.48M	$-10.58M
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Sagimet Biosciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. SGMT's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Sagimet Biosciences SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	1	-	-	-	-	-	-
SG&A	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	-	-	-	-	$6.99M	-	-	-	-	-	-
High Forecast	-	-	-	-	$6.99M	-	-	-	-	-	-
Low Forecast	-	-	-	-	$6.99M	-	-	-	-	-	-
Surprise %	-	-	-	-	-	-	-	-	-	-	-

Sagimet Biosciences's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to SGMT last annual SG&A of $NaN (undefined).

Sagimet Biosciences EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24
# Analysts	-	-	-	-	1	-	-	-	-	-	-
EPS	-	-	-	-	-	-	-	-	-	-	-
Avg Forecast	$-1.05	$-1.01	$-0.98	$-0.99	$-0.89	$-0.88	$-0.84	$-0.68	$-0.56	$-0.39	$-0.33
High Forecast	$-1.05	$-1.01	$-0.98	$-0.99	$-0.89	$-0.88	$-0.84	$-0.56	$-0.48	$-0.39	$-0.33
Low Forecast	$-1.05	$-1.01	$-0.98	$-0.99	$-0.89	$-0.88	$-0.84	$-0.80	$-0.66	$-0.39	$-0.33
Surprise %	-	-	-	-	-	-	-	-	-	-	-

According to undefined Wall Street analysts, Sagimet Biosciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to SGMT previous annual EPS of $NaN (undefined).

SGMT Forecast FAQ

Is Sagimet Biosciences a good buy?

Yes, according to 6 Wall Street analysts, Sagimet Biosciences (SGMT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 83.33% of SGMT's total ratings.

What is SGMT's price target?

Sagimet Biosciences (SGMT) average price target is $6 with a range of $6 to $6, implying a 36.05% from its last price of $4.41. The data is based on 6 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Sagimet Biosciences stock go up soon?

According to Wall Street analysts' prediction for SGMT stock, the company can go up by 36.05% (from the last price of $4.41 to the average price target of $6), up by 36.05% based on the highest stock price target, and up by 36.05% based on the lowest stock price target.

Can Sagimet Biosciences stock reach $7?

SGMT's average twelve months analyst stock price target of $6 does not support the claim that Sagimet Biosciences can reach $7 in the near future.

What are Sagimet Biosciences's analysts' financial forecasts?

Sagimet Biosciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $3.33M (high $3.33M, low $3.33M), average EBITDA is $2M (high $2M, low $2M), average net income is $-106M (high $-102M, low $-109M), average SG&A $6.99M (high $6.99M, low $6.99M), and average EPS is $-3.283 (high $-3.165, low $-3.401). SGMT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-130M (high $-130M, low $-130M), average SG&A $0 (high $0, low $0), and average EPS is $-4.03 (high $-4.03, low $-4.03).